Hemodynamic Monitoring Market Size and Share

Hemodynamic Monitoring Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Hemodynamic Monitoring Market Analysis by Mordor Intelligence

The Hemodynamic Monitoring Market size is estimated at USD 1.19 billion in 2025, and is expected to reach USD 1.45 billion by 2030, at a CAGR of 4.07% during the forecast period (2025-2030).

Growth remains steady rather than rapid because providers prioritize cost control and outcome gains, steering investments toward non-invasive platforms and AI-powered analytics that cut complications and staff workload. Aging populations in North America, Europe, Japan, and increasingly China lift the clinical demand curve for continuous cardiovascular surveillance, while hospital-at-home models open fresh demand pockets for remote monitoring hardware and software. Manufacturers respond by integrating goal-directed therapy algorithms, sepsis early-warning scores, and predictive blood-pressure indices into unified dashboards that shorten ICU stays. Competitive dynamics intensified after BD bought Edwards Lifesciences’ Critical Care unit. This deal immediately gave the buyer the largest installed base of intelligent monitors and set an acquisition premium for end-to-end platforms.

Key Report Takeaways

  • By system type, minimally invasive technologies held 42.11% of the hemodynamic monitoring market share in 2024, while non-invasive systems are forecast to grow at a 5.01% CAGR to 2030. 
  • By device, pulmonary artery catheters led with 29.54% of the hemodynamic monitoring market size in 2024; wearable doppler ultrasound patches are poised to expand at a 7.65% CAGR through 2030. 
  • By end user, hospitals and clinics commanded 51.92% of the hemodynamic monitoring market size in 2024; home-care and remote monitoring settings show the fastest growth at a 4.75% CAGR. 
  • By geography, North America controlled 40.20% revenue share in 2024, whereas Asia-Pacific is projected to register the highest regional CAGR of 6.13% to 2030. 

Segment Analysis

By System Type: Non-Invasive Technologies Drive Innovation

Minimally invasive platforms captured 42.11% of the hemodynamic monitoring market share in 2024, reflecting decades of clinician familiarity and detailed waveform analytics. Yet non-invasive systems top the growth league at a 5.01% CAGR, propelled by miniaturized sensors that match catheter precision and by payer pressure to limit infection-related extensions of stay. Across ICUs and step-down units, staff now rotate between cuffless blood-pressure cuffs for stable cases and arterial-waveform modules for acute decompensation within unified workstations. Hospitals cite reduced line-care costs and faster mobilization to justify capital spending. 

Demand momentum signals a structural pivot: vendors bundle impedance cardiography, Doppler ultrasound, and photoplethysmography channels into one dockable chassis, meeting multiple acuity tiers with a single fleet. Software upgrades introduce deep-learning stroke-volume variation calculations that alert staff long before hypotension manifests, embedding clinical decision support at the bedside. As a result, the hemodynamic monitoring market size for non-invasive modalities is projected to add USD 160 million new revenue between 2025 and 2030, narrowing the gap with legacy invasive systems.

Hemodynamic Monitoring Market: Market Share by System Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By Device: Wearable Technologies Disrupt Traditional Monitoring

Pulmonary artery catheters still underpin 29.54% of 2024 revenue due to unmatched mixed-venous oxygen saturation trending in complex cardiac cases. Nevertheless, wearable Doppler ultrasound patches book the swiftest ascent at a 7.65% CAGR, buoyed by favorable human-factors scores and infection-risk elimination. Early adopters document nursing-time savings of 20 minutes per patient per shift when ultrasound patches replace manual cuff cycles. 

AI further tilts the field. Edwards’ Acumen Hypotension Prediction Index trims intra-operative hypotension by 57% and ships pre-installed on multiple hardware lines, protecting catheter share while preparing a runway for wearable hybrids. Parallel innovation in volume-clamp rings and bioreactance vests foretell multimodal wearables that stream flow, pressure, and biochemical markers to cloud dashboards. Correspondingly, the hemodynamic monitoring market size for wearables is forecast to climb at twice the pace of any catheter segment, underscoring the shift toward untethered continuous care.

By End User: Remote Monitoring Reshapes Care Delivery

Hospitals and clinics retained 51.92% of 2024 revenue because acute shock and major surgery still require in-house invasive tools. Yet the remote-monitoring category posts a 4.75% CAGR on the back of Medicare billing codes that reimburse up to USD 48 per 30-day cycle for home physiologic monitoring. Health systems pilot hospital-at-home programs where congestive-heart-failure patients receive wireless Doppler patches and tablet dashboards, cutting readmissions by 15%. 

Ambulatory surgery centers and cath labs also broaden procurement as day-surgery volumes climb, demanding lightweight monitors that roll between procedure rooms. Vendors differentiate through cellular gateways, ensuring continuity of data from the OR to the recovery ward to the living room. This continuum fosters subscription revenues for cloud analytics, turning device makers into service providers and reshaping cash-flow profiles across the hemodynamic monitoring market.

Hemodynamic Monitoring Market: Market Share by End User
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

Geography Analysis

North America led with 40.20% revenue share in 2024. Market dominance stems from robust ICU infrastructure, favorable private-payer contracts, and early integration of AI modules into perioperative workflows. The region adopts bundled-payment models that reward fewer complications, aligning economic incentives with algorithmic early-warning systems. Partnerships such as Philips and Mass General Brigham’s live-data collaboration illustrate demand for enterprise-scale analytics platforms. 

Asia-Pacific is the fastest-growing region, with a 6.13% CAGR through 2030. China fuels half the regional gain under Healthy China 2030 policies that subsidize advanced monitors in Tier-2 city hospitals. Japan’s conditional approval pathway shortens time-to-market for breakthrough devices, while India’s expanding middle class spurs private-hospital chains to deploy non-invasive cardiac output modules. Private equity flows into Asian telehealth portfolios further accelerate the hemodynamic monitoring market by financing remote patient monitoring rollouts. 

Europe sustains measured expansion anchored in guideline standardization and perioperative care optimization. ERAS Society endorsements drive procurement of stroke-volume variation monitors across surgical wards. Although Brexit injects dual regulatory pathways, mutual-recognition arrangements keep supply chains stable. Tender committees increasingly demand evidence of cost-utility alongside performance, favoring platforms with peer-reviewed outcome data. 

Hemodynamic Monitoring Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Get Analysis on Important Geographic Markets
Download PDF

Competitive Landscape

Consolidation intensified when BD acquired Edwards’ Critical Care portfolio for USD 4.2 billion in 2024, integrating smart sensors, predictive indices, and infusion interoperability under one umbrella. The deal trumped annual sector revenue threefold, highlighting the premium investors place on end-to-end ecosystems that marry hardware with AI. 

Incumbents such as Philips, Masimo, and GE HealthCare respond by embedding cloud-edge analytics and expanding into ward-level deployments. Masimo’s Radius VSM combines multi-parameter bedside monitoring with tetherless wearable transport sensors, underscoring a push toward single-vendor longitudinal coverage from ICU to discharge. GE HealthCare’s Portrait VSM plans to integrate continuous non-invasive blood pressure with machine-learning deterioration scores, positioning the firm for step-down unit growth. 

Disruptors focus on biomarker convergence. Start-ups prototype patch-based lactate sensors and nano-fluidic troponin detectors that could merge hemodynamics with metabolic surveillance, creating new clinical workflows. Partnerships with academic medical centers accelerate validation while leveraging hospital equity stakes for channel access. Competitive intensity is set to remain high as platforms vie to own the primary clinician interface within the hemodynamic monitoring market.

Hemodynamic Monitoring Industry Leaders

  1. Koninklijke Philips NV

  2. Edwards Lifesciences Corporation

  3. LiDCO Group PLC

  4. Getinge AB

  5. GE HealthCare Technologies Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Hemodynamic Monitoring Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • April 2025: BD launched HemoSphere Alta, an advanced hemodynamic monitoring platform featuring AI-driven algorithms, including the Cerebral Autoregulation Index (CAI) for brain blood flow stability assessment and enhanced Acumen Hypotension Prediction Index capabilities. This next-generation platform represents a significant advancement in AI-powered clinical decision support for hemodynamic management.
  • April 2025: Teleflex received FDA 510(k) clearance for the AC3 Range Intra-Aortic Balloon Pump (IABP), designed specifically for reliable cardiac support during patient transport with proprietary algorithms and dual power options for challenging transport environments
  • February 2025: Teleflex announced acquisition of BIOTRONIK's Vascular Intervention business for approximately EUR 760 million (USD 820 million), expanding its interventional cardiology portfolio and enhancing innovation pipeline with resorbable scaffold technologies
  • September 2024: Becton, Dickinson, and Company completed the acquisition of Edwards Lifesciences’ critical care product group, which was rebranded as BD Advanced Patient Monitoring. This acquisition enhanced BD's portfolio of smart, connected care solutions by incorporating advanced monitoring technologies and AI-powered clinical decision tools. The technologies from BD Advanced Patient Monitoring were often utilized alongside the BD Alaris Infusion System in operating rooms and intensive care units.
  • July 2024: Edwards Lifesciences agreed to acquire JenaValve and Endotronix for approximately USD 1.2 billion, with Endotronix's Cordella Pulmonary Artery Sensor System receiving FDA approval for heart failure monitoring.

Table of Contents for Hemodynamic Monitoring Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Critically Ill Geriatric Population
    • 4.2.2 Rising Prevalence of Cardiovascular Disorders and Diabetes
    • 4.2.3 Technological Advancements in Minimally and Non-invasive Monitoring
    • 4.2.4 Growing Adoption of Hemodynamic Optimization During ERAS Protocols
    • 4.2.5 AI-driven Predictive Analytics for Early Sepsis and Shock Detection
    • 4.2.6 Wearable Doppler Ultrasound Patches Enabling Remote Monitoring
  • 4.3 Market Restraints
    • 4.3.1 Complications Associated with Invasive Monitoring Systems
    • 4.3.2 Stringent FDA / CE Approval Pathways
    • 4.3.3 Alarm Fatigue & Data Overload Reducing Clinical Uptake
    • 4.3.4 Reimbursement Gaps for Peri-operative Optimization Bundles
  • 4.4 Technological Outlook
  • 4.5 Porter’s Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers / Consumers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitute Products
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

  • 5.1 By System Type
    • 5.1.1 Minimally Invasive Monitoring Systems
    • 5.1.2 Invasive Monitoring Systems
    • 5.1.3 Non-invasive Monitoring Systems
  • 5.2 By Device
    • 5.2.1 Pulmonary Artery Catheters
    • 5.2.2 Pulse Contour Analysis Devices
    • 5.2.3 Esophageal Doppler Systems
    • 5.2.4 Electrical/Bio-impedance and Bio-reactance Monitors
    • 5.2.5 Volume Clamp / CNAP Devices
    • 5.2.6 Wearable Doppler Ultrasound Patches
    • 5.2.7 Other Devices
  • 5.3 By End User
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Cath Labs and Diagnostic Centers
    • 5.3.4 Home-care and Remote Patient Monitoring
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Edwards Lifesciences Corp.
    • 6.3.2 Koninklijke Philips N.V.
    • 6.3.3 Getinge AB
    • 6.3.4 Baxter International Inc.
    • 6.3.5 GE HealthCare Technologies Inc.
    • 6.3.6 ICU Medical Inc.
    • 6.3.7 Draegerwerk AG & Co. KGaA
    • 6.3.8 Masimo Corp.
    • 6.3.9 LiDCO Group PLC
    • 6.3.10 Deltex Medical Group PLC
    • 6.3.11 Tensys Medical Inc.
    • 6.3.12 CNSystems Medizintechnik GmbH
    • 6.3.13 Terumo Corp.
    • 6.3.14 Mindray Bio-Medical Electronics Co.
    • 6.3.15 Nihon Kohden Corp.
    • 6.3.16 Schwarzer Cardiotek GmbH
    • 6.3.17 Uscom Ltd.
    • 6.3.18 Flosonics Medical
    • 6.3.19 Smiths Medical
    • 6.3.20 Change Healthcare

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Research Methodology Framework and Report Scope

Market Definitions and Key Coverage

Our study defines the hemodynamic monitoring market as the value generated by newly manufactured invasive, minimally invasive, and non-invasive systems whose prime function is to track real-time blood flow, pressure, and oxygenation parameters in critically ill adult and pediatric patients across hospital ICUs, cath labs, and step-down units. Disposable catheters, pressure transduction sets, and system software upgrades are included because they are purchased expressly for these monitors.

Scope Exclusions: Stand-alone wearable fitness or ambulatory blood pressure patches sold for home wellness programs are not captured within this scope.

Segmentation Overview

  • By System Type
    • Minimally Invasive Monitoring Systems
    • Invasive Monitoring Systems
    • Non-invasive Monitoring Systems
  • By Device
    • Pulmonary Artery Catheters
    • Pulse Contour Analysis Devices
    • Esophageal Doppler Systems
    • Electrical/Bio-impedance and Bio-reactance Monitors
    • Volume Clamp / CNAP Devices
    • Wearable Doppler Ultrasound Patches
    • Other Devices
  • By End User
    • Hospitals and Clinics
    • Ambulatory Surgical Centers
    • Cath Labs and Diagnostic Centers
    • Home-care and Remote Patient Monitoring
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Detailed Research Methodology and Data Validation

Primary Research

Interviews were conducted with ICU physicians, biomedical engineers, supply chain managers, and regional distributors across North America, Europe, and Asia Pacific. Their insights validated device mix shifts toward non-invasive platforms, clarified average replacement cycles, and refined pricing dispersion that is rarely detailed in secondary literature.

Desk Research

Mordor analysts first reviewed publicly available datasets from sources such as the World Health Organization, the OECD health statistics portal, the Centers for Medicare and Medicaid Services, and national device registries to size procedure pools and installed base ratios. We then gathered shipment and average selling price clues from listed company filings, quarterly transcripts, and select regulatory submissions. Trade associations, for instance, the American College of Cardiology and the European Society of Intensive Care Medicine, offered prevalence benchmarks and clinical adoption guidelines that sharpened utilization rates. Paid databases like D&B Hoovers and Dow Jones Factiva supplied hard revenue splits and news on tender volumes. This list is illustrative; numerous other credible publications informed the desk review.

Market-Sizing & Forecasting

A top-down pool of critical care beds by country was paired with average monitor penetration and refresh cadence to estimate 2024 installed units; results were cross-checked with sampled supplier roll-ups (bottom up) and disposable per procedure calculations. Key variables fueling the model include cardiac surgery volumes, sepsis incidence, ICU bed additions, device ASP trajectories, reimbursement changes, and non-invasive technology uptake. Multivariate regression, vetted through expert consensus, projects each driver to 2030, while scenario analysis cushions for currency volatility and procurement lulls. Data gaps in smaller countries were bridged using regional proxy ratios vetted during primary calls.

Data Validation & Update Cycle

Outputs pass a three-layer review: automated variance scans, senior analyst peer checks, and a lead analyst sign-off. We refresh the model every twelve months and trigger interim updates when material events, major M&A or regulatory shifts, arise. Clients always receive the most recent validated baseline.

Why Mordor's Hemodynamic Monitoring Baseline Earns Unmatched Trust

Published market values often diverge because firms frame device scope differently, select unique base years, and refresh models at varied intervals.

Key gap drivers include the inclusion of ambulatory pressure patches by some publishers, revenue roll-ups that bundle disposables with unrelated patient monitors, reliance on older 2018 base years, and limited primary validation that leaves local ASP skews unchecked.

Benchmark comparison

Market Size Anonymized source Primary gap driver
USD 1.19 B (2025) Mordor Intelligence -
USD 1.67 B (2025) Global Consultancy A Bundles remote and ward monitors, revenue roll-up approach, biennial refresh
USD 1.20 B (2023) Trade Journal B Excludes disposables, historic currency base, minimal primary checks
USD 2.37 B (2024) Data Aggregator C Combines broader patient monitoring families, models demand via patient prevalence rather than device installs

These comparisons show that Mordor Intelligence anchors its estimate on clearly defined device boundaries, annually updated multivariate drivers, and cross-verified field inputs, producing a balanced and reproducible baseline that decision makers can trust.

Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the hemodynamic monitoring market?

The market generated USD 1.19 billion in 2025 and is projected to reach USD 1.45 billion by 2030 at a 4.07% CAGR.

Which system type is growing the fastest?

Non-invasive systems are expanding at a 5.01% CAGR, outpacing minimally invasive and invasive counterparts as hospitals aim to minimize infection risk and improve patient comfort.

How did BD’s acquisition of Edwards Lifesciences impact competition?

The USD 4.2 billion deal created the largest integrated platform spanning invasive and non-invasive modalities, raising the consolidation level across the hemodynamic monitoring market.

Why is Asia-Pacific considered the key growth region?

Aging demographics, expanding hospital infrastructure, and supportive regulatory reforms are driving a 6.13% CAGR in Asia-Pacific, the highest globally.

What role does artificial intelligence play in hemodynamic monitoring?

AI algorithms enable early detection of hypotension, sepsis, and cerebral perfusion issues, improving outcomes and justifying premium pricing for advanced monitoring suites.

How are reimbursement changes influencing adoption?

New Medicare codes for remote physiologic monitoring and European tariffs for non-invasive cardiac output trending are accelerating uptake in home-care and post-acute settings.

Page last updated on:

Hemodynamic Monitoring Market Report Snapshots